April
9, 1999
FOR IMMEDIATE RELEASE
Contact: Laura Livingston, 703-299-1012
ASCO CALLS FOR REAL
"PATIENTS’ BILL OF RIGHTS," INCLUDING COVERAGE OF CLINICAL
TRIALS
The American Society of Clinical Oncology (ASCO) applauds Senate
Minority Leader Tom Daschle, Senator Edward Kennedy and Congressman
John Dingell for the inclusion of clinical trials coverage in the
"Patients Bill of Rights Act"(S. 6/H.R. 358).
ASCO, which is the national medical specialty society
representing over 12,000 cancer specialists involved in clinical
research and patient care, is committed to the provision of
insurance coverage for clinical trials for cancer patients. "For
people with serious or life-threatening diseases, curative treatment
often is not available," said Allen S. Lichter, M.D., President of
ASCO. "For those patients, access to state-of-the-art therapy
through high-quality clinical trials, offers an important treatment
option, as well as the opportunity to advance medical
knowledge."
Many third-party payors – including the Medicare program –
specifically exclude coverage of "experimental" or "investigational"
treatments. This coverage limitation is intended to protect the
patient from treatment that may be harmful or of no therapeutic
value. Increasingly, however, this policy has been used to deny
coverage for high-quality therapy in clinical trials. It is,
therefore, ASCO’s position that any insurance reform measure in
Congress must recognize the appropriate role of clinical trials for
people with serious or life-threatening diseases and must provide
coverage for the patient care costs incurred in clinical trials.
Last year, the President’s Advisory Commission on Consumer
Protection and Quality in the Health Care Industry identified
eliminating barriers to consumer participation in clinical trials as
one of six major goals for continuing national health reform. One
such barrier is exclusion by health plans of any care provided in
the context of a clinical trial. "Unless payors provide access to
and coverage of costs associated with approved clinical trials for
cancer and other life-threatening diseases, patients will be denied
access to promising therapies," added Lichter. "Some will be denied
their only chance for survival or improved quality of life."
# # #
Return to
ASCO General News Releases |